Vanguard Global Advisers’s Cytosorbents CTSO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.71K Buy
694
+1
+0.1% +$7 ﹤0.01% 3641
2026
Q2
$5.19K Hold
693
– – ﹤0.01% 3548
2026
Q1
$7.85K Buy
+693
New +$9.46K ﹤0.01% 3505

Other funds holding CTSO

Vanguard Global Advisers's CTSO Position: Q3 2026 in Review

Vanguard Global Advisers increased its Cytosorbents (CTSO) stake by 0.14% in Q3 2026, buying an estimated $7 and bringing the position to 694 shares worth $2.71K. The position accounts for ﹤0.01% of the portfolio, ranked #3641.

Vanguard Global Advisers first reported a position in CTSO in Q1 2026 and has held it in 3 quarters since. The position peaked at $7.85K in Q1 2026. 28 funds tracked by Wall St. Rank hold CTSO as of Q3 2026.

  • Vanguard Global Advisers held 694 shares of Cytosorbents worth $2.71K as of Q3 2026.
  • Vanguard Global Advisers bought 1 Cytosorbents share in Q3 2026, an estimated $7.
  • Cytosorbents made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3641 holding.
  • Vanguard Global Advisers first reported a position in Cytosorbents in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Cytosorbents position peaked at $7.85K in Q1 2026.
  • 28 funds tracked by Wall St. Rank held Cytosorbents as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.